TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36875134

Group type: EXPERIMENTAL
Intervention: BCG vaccination in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG vaccination in the afternoon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of morning vs afternoon BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG vaccination (morning and afternoon)
Number of subjects: 0
Study: 36875317

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) 0.15 mg/kg or MNTX 8 mg/12 mg based on body weight, administered subcutaneously every other day.
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 364
Study: 36875554

Group type: EXPERIMENTAL
Intervention: Mucous Fistula Refeeding (MFR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36875669

Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in supine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: SCES on (5 mA) in tilt
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in supine at assessment two
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Decreasing amplitude to 2 mA
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: SCES on (3 mA) in tilt at assessment two
Number of subjects: 1

Group type: COMPARATOR
Intervention: SCES off
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: SCES on
Number of subjects: 1
Study: 36875717

Group type: EXPERIMENTAL
Intervention: Itraconazole and Hydroxychloroquine
Number of subjects: 11
Study: 36876292

Group type: EXPERIMENTAL
Intervention: Palliative care interventions initiated by the study team
Number of subjects: 133
Study: 36876350

Group type: COMPARATOR
Intervention: First-line anti-TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol)
Number of subjects: 43
Study: 36876480

Group type: EXPERIMENTAL
Intervention: Persistent smokers
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Smokers who quit at 3 months
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2874

Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 2874

Group type: COMPARATOR
Intervention: Persistent smokers vs. never smokers
Number of subjects: 2874
Study: 36876483

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 5258

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 5258
Study: 36876594

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study: 36876735

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study: 36876753

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Medical therapy (control)
Number of subjects: 350
Study: 36876756

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair plus medical therapy (device group)
Number of subjects: 614

Group type: COMPARATOR
Intervention: Maximal doses of guideline-directed medical therapy alone (control group)
Number of subjects: 614
Study: 36876740

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (180 mg daily)
Number of subjects: 13970

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study: 36876946

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) targeting arm motor function; 36 sessions of 70 minutes each over 6 weeks, half supervised via videoconference; included functional games, exercise videos, education, and daily assessments.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (not detailed in the abstract)
Number of subjects: 19
Study: 36876957

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2062
Study: 36877099

Group type: EXPERIMENTAL
Intervention: Taletrectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Entrectinib
Number of subjects: 0
Study: 36877098

Group type: EXPERIMENTAL
Intervention: Sotatercept (0.3 mg/kg starting dose, 0.7 mg/kg target dose, subcutaneous every 3 weeks)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 323
Study: 36877118

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Number of subjects: 300
Study: 36877132

Group type: EXPERIMENTAL
Intervention: Active placebo
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Standard placebo
Number of subjects: 1462
Study: 36877177

Group type: EXPERIMENTAL
Intervention: Coordinated, multifaceted intervention
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1049
Study: 36877234

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 522
Study: 36877259

Group type: EXPERIMENTAL
Intervention: Bionic pancreas (BP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Backup insulin regimens generated by the BP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting insulin dose, four-period basal insulin profile, short-acting meal doses, glucose correction factor
Number of subjects: 0
Study: 36877480

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), delivered weekly for 16 weeks
Number of subjects: 64
Study: 36877502

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (coronary angiography and revascularization if feasible; n=84)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conservative strategy (medical treatment with coronary angiography for recurrent ischemia; n=83)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy
Number of subjects: 167
Study: 36877543

Group type: EXPERIMENTAL
Intervention: Digital psychological intervention (self-guided internet intervention for chronic pain)
Number of subjects: 85
Study: 36877563

Group type: EXPERIMENTAL
Intervention: Gamified rehabilitation equipment 3 times a week
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 57
Study: 36877575

Group type: EXPERIMENTAL
Intervention: Ophthalmic involvement at diagnosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isolated bilateral proptosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diplopia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other ophthalmic abnormalities
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall trends in pediatric cases
Number of subjects: 20
Study: 36877666

Group type: EXPERIMENTAL
Intervention: Triple-layered cloth facemask
Number of subjects: 9
Study: 36877726

Group type: EXPERIMENTAL
Intervention: Long health itinerary (admitted >3 days after fever onset)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Bloodstream infection (specifically non-typhoidal Salmonella)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Delaying factors (consulting traditional, private and/or multiple providers, rural residence, prehospital intravenous therapy, and prehospital overnight stays)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Use of antibiotics reserved for hospital use, intravenous therapy, and prehospital overnight stays
Number of subjects: 784
Study: 36877800

Group type: EXPERIMENTAL
Intervention: Grief COVID web-based intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 114
Study: 36877807

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy (LDL-C target between 50 and 70 mg/dL)
Number of subjects: 4400

Group type: COMPARATOR
Intervention: High-intensity statin treatment (rosuvastatin 20 mg or atorvastatin 40 mg)
Number of subjects: 4400

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy
Number of subjects: 4400
Study: 36877964

Group type: EXPERIMENTAL
Intervention: Over-the-scope clips (OTSCs)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard hemostatic treatment
Number of subjects: 190
Study: 36878187

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham IPC
Number of subjects: 20
Study: 36878213

Group type: EXPERIMENTAL
Intervention: TAK-003 vaccine
Number of subjects: 20067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20067
Study: 36878216

Group type: EXPERIMENTAL
Intervention: SDF+KI
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: SDF
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: RMGIC
Number of subjects: 49
Study: 36878237

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks plus chemotherapy (paclitaxel 175 mg/m2)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2)
Number of subjects: 617
Study: 36878239

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 17160
Study: 36878264

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1623

Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 1623
Study: 36878302

Group type: EXPERIMENTAL
Intervention: Endoscopist-facilitated intubation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard intubation
Number of subjects: 45
Study: 36878311

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism (SubHypo)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Euthyroid
Number of subjects: 253
Study: 36878326

Group type: EXPERIMENTAL
Intervention: APOE4/CCR5 knockout heterozygotes
Number of subjects: 2

Group type: COMPARATOR
Intervention: APOE4/wild-type heterozygotes
Number of subjects: 2
Study: 36878389

Group type: EXPERIMENTAL
Intervention: Centralized care (smoking cessation and SDM delivered remotely by trained counselors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (providers delivering smoking cessation and SDM on site)
Number of subjects: 0
Study: 36878649

Group type: EXPERIMENTAL
Intervention: QC-POD intervention (periopeartive intervention at least two times per day, delirium screening, non-pharmacological preventive measures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline control period (no specific intervention mentioned)
Number of subjects: 0
Study: 36878658

Group type: EXPERIMENTAL
Intervention: Safe at Home programme
Number of subjects: 202

Group type: COMPARATOR
Intervention: Waitlisted group
Number of subjects: 202
Study: 36878666

Group type: EXPERIMENTAL
Intervention: Exercise and education (12-week supervised)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exercise and education
Number of subjects: 63
Study: 36878672

Group type: EXPERIMENTAL
Intervention: Acoustic CAD-score device with a cut-off ≤20 for obstructive CAD rule-out
Number of subjects: 1683

Group type: EXPERIMENTAL
Intervention: Acoustic CAD-score device with a cut-off ≤20 applied in ESC-PTP 5% to <15% patients
Number of subjects: 1683
Study: 36878701

Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 71

Group type: COMPARATOR
Intervention: Tenecteplase (TNK) and Alteplase
Number of subjects: 71
Study: 36878715

Group type: EXPERIMENTAL
Intervention: Airdoc retinal artificial intelligence system (ARAS) for detecting multiple fundus diseases
Number of subjects: 4795

Group type: EXPERIMENTAL
Intervention: Airdoc retinal artificial intelligence system (ARAS)
Number of subjects: 4795
Study: 36878722

Group type: EXPERIMENTAL
Intervention: Ultra-early neurologic improvement (U-RNI) defined as improvement by 2 or more points on the Los Angeles Motor Scale (LAMS) score between prehospital and early post-ED arrival examinations.
Number of subjects: 1245

Group type: EXPERIMENTAL
Intervention: U-RNI
Number of subjects: 1245
Study: 36878897

Group type: EXPERIMENTAL
Intervention: Thermostable ID93 + GLA-SE vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-thermostable two-vial vaccine presentation
Number of subjects: 0
Study: 36879012

Group type: EXPERIMENTAL
Intervention: anti-EGFR-ILs-dox 50 mg/m²
Number of subjects: 48
Study: 36879078

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Eating Disorders (CBT-E)
Number of subjects: 63
Study: 36879087

Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg BID
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 36879107

Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: T1DM patients
Number of subjects: 282

Group type: COMPARATOR
Intervention: Rituximab therapy in T1DM patients
Number of subjects: 282

Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 282
Study: 36879129

Group type: EXPERIMENTAL
Intervention: Intravenous evinacumab 15 mg/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 36879199

Group type: EXPERIMENTAL
Intervention: ADCS-ADL-MCI scale at baseline
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: ADCS-ADL-MCI scale at 36 months
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Convergent/discriminant validity
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Known-groups validity
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Responsiveness
Number of subjects: 769
Study: 36879201

Group type: EXPERIMENTAL
Intervention: Digital music and movement intervention (12 weeks, 4 sessions per week)
Number of subjects: 49
Study: 36879259

Group type: EXPERIMENTAL
Intervention: Technology-assisted intervention for resolving unaddressed legal issues
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 800
Study: 36879265

Group type: EXPERIMENTAL
Intervention: Group A (low muscle mass and strength)
Number of subjects: 171
Study: 36879284

Group type: EXPERIMENTAL
Intervention: Tislelizumab monotherapy
Number of subjects: 0
Study: 36879292

Group type: EXPERIMENTAL
Intervention: High-calorie food images versus baseline (H vs. X)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-calorie food images versus baseline (L vs. X)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-calorie food images versus low-calorie food images (H vs. L)
Number of subjects: 20
Study: 36879301

Group type: EXPERIMENTAL
Intervention: Mentalization-based therapy (MBT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 175
Study: 36879297

Group type: EXPERIMENTAL
Intervention: Milk fermented by Lacticaseibacillus rhamnosus CNCM I-3690
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Milk fermented by Streptococcus thermophilus CNCM I-1630 and Lactobacillus delbrueckii subsp. bulgaricus CNCM I-1519
Number of subjects: 16

Group type: COMPARATOR
Intervention: Chemically acidified milk (placebo)
Number of subjects: 16
Study: 36879314

Group type: EXPERIMENTAL
Intervention: SexHealth Mobile intervention (same-day, onsite clinical consultation and contraception)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: SexHealth Mobile intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 98
Study: 36879333

Group type: EXPERIMENTAL
Intervention: Active phase of the augmented platform (orientation cueing during location recording)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive phase of the augmented platform (only recording location)
Number of subjects: 0
Study: 36879386

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) use
Number of subjects: 18

Group type: COMPARATOR
Intervention: Better hearing ear alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Children with normal hearing (NH)
Number of subjects: 18
Study: 36879424

Group type: EXPERIMENTAL
Intervention: Alirocumab with statin therapy (after achieving very low LDL-C levels)
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo with statin therapy
Number of subjects: 18924
Study: 36879584

Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin (A-PRF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 15
Study: 36879786

Group type: EXPERIMENTAL
Intervention: KL-A167 900mg intravenously once every 2 weeks until confirmed disease progression, intolerable toxicity, or withdrawal of informed consent
Number of subjects: 153
Study: 36880049

Group type: EXPERIMENTAL
Intervention: IHAT (iron hydroxide adipate tartrate)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Ferrous sulphate (FeSO4)
Number of subjects: 642
Study: 36880127

Group type: EXPERIMENTAL
Intervention: Osteocalcin
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Osteoprotegerin
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 848
Study: 36880261

Group type: EXPERIMENTAL
Intervention: Cognitive stress response using an arithmetic task in patients with HT&DM
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive stress response using an arithmetic task in patients with HT
Number of subjects: 62
Study: 36880426

Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge in CRICKET trial
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Cetuximab rechallenge in CAVE trial
Number of subjects: 46
Study: 36880866

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery with faster insulin aspart (Fiasp)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard insulin aspart (IAsp)
Number of subjects: 25
Study: 36880910

Group type: EXPERIMENTAL
Intervention: SMS + NRT
Number of subjects: 35

Group type: COMPARATOR
Intervention: SMS + NRT + coaching
Number of subjects: 35
Study: 36880917

Group type: EXPERIMENTAL
Intervention: Online predeparture intervention focused on risk and protective factors
Number of subjects: 650
Study: 36880945

Group type: EXPERIMENTAL
Intervention: MR fingerprinting sequence with water and fat separation for ECV quantification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fat fraction (FF) quantification
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water relaxation time quantification
Number of subjects: 0
Study: 36880949

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) for PTMC with US-detected capsular invasion
Number of subjects: 461

Group type: COMPARATOR
Intervention: Microwave ablation (MWA) for PTMC without US-detected capsular invasion
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 461
Study: 36881032

Group type: EXPERIMENTAL
Intervention: Olamkicept 600 mg
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Olamkicept 300 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 36881034

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (2 g)
Number of subjects: 11983

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11983
Study: 36881247

Group type: EXPERIMENTAL
Intervention: ACLD patients
Number of subjects: 249

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 249
Study: 36881285

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: cDMARDs
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Presence of myalgia
Number of subjects: 141
Study: 36881394

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 739

Group type: COMPARATOR
Intervention: Not frail
Number of subjects: 739

Group type: COMPARATOR
Intervention: Prefrail
Number of subjects: 739

Group type: COMPARATOR
Intervention: Frail
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Frailty status at baseline
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Frailty change
Number of subjects: 739
Study: 36881421

Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: RbPET
Number of subjects: 1732
Study: 36881446

Group type: EXPERIMENTAL
Intervention: VACT-CP (Veteran ACT for Chronic Pain)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist and treatment-as-usual control
Number of subjects: 20
Study: 36881458

Group type: EXPERIMENTAL
Intervention: Adherence to controller medication (inhaled corticosteroids)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unmet social needs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Scarcity and future discounting
Number of subjects: 200
Study: 36881542

Group type: EXPERIMENTAL
Intervention: Preoperative treatment for anemia and/or iron deficiency
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Postoperative treatment for anemia and/or iron deficiency
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency at D-1/D0
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Prevalence of iron deficiency at D30
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Percentage of patients with anemia and/or iron deficiency at D-1/D0
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Percentage of patients with anemia and/or iron deficiency at D30
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Percentage of patients with both anemia and iron deficiency at D-1/D0
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Percentage of patients with both anemia and iron deficiency at D30
Number of subjects: 1494
Study: 36881575

Group type: EXPERIMENTAL
Intervention: Automated 360-degree goniophotography using the NIDEK Gonioscope GS-1
Number of subjects: 20
Study: 36881769

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36881780

Group type: EXPERIMENTAL
Intervention: IN-alert HF state (multi-sensor HeartLogic Index >16)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: RDI ≥ 30 episodes/h (severe sleep apnea)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Combination of IN-alert HF state and RDI ≥ 30 episodes/h
Number of subjects: 411
Study: 36881782

Group type: EXPERIMENTAL
Intervention: Pelabresib and ruxolitinib
Number of subjects: 84
Study: 36881820

Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36881899

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36881901

Group type: EXPERIMENTAL
Intervention: Experimental sleep disturbances (ESDs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sleep control protocol (8-hour sleep opportunity)
Number of subjects: 24